Literature DB >> 20047977

Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium.

Christine F Skibola1, Paige M Bracci, Alexandra Nieters, Angela Brooks-Wilson, Silvia de Sanjosé, Ann Maree Hughes, James R Cerhan, Danica R Skibola, Mark Purdue, Eleanor Kane, Qing Lan, Lenka Foretova, Maryjean Schenk, John J Spinelli, Susan L Slager, Anneclaire J De Roos, Martyn T Smith, Eve Roman, Wendy Cozen, Paolo Boffetta, Anne Kricker, Tongzhang Zheng, Tracy Lightfoot, Pierluigi Cocco, Yolanda Benavente, Yawei Zhang, Patricia Hartge, Martha S Linet, Nikolaus Becker, Paul Brennan, Luoping Zhang, Bruce Armstrong, Alex Smith, Renee Shiao, Anne J Novak, Marc Maynadie, Stephen J Chanock, Anthony Staines, Theodore R Holford, Elizabeth A Holly, Nathaniel Rothman, Sophia S Wang.   

Abstract

In an International Lymphoma Epidemiology Consortium pooled analysis, polymorphisms in 2 immune-system-related genes, tumor necrosis factor (TNF) and interleukin-10 (IL10), were associated with non-Hodgkin lymphoma (NHL) risk. Here, 8,847 participants were added to previous data (patients diagnosed from 1989 to 2005 in 14 case-control studies; 7,999 cases, 8,452 controls) for testing of polymorphisms in the TNF -308G>A (rs1800629), lymphotoxin-alpha (LTA) 252A>G (rs909253), IL10 -3575T>A (rs1800890, rs1800896), and nucleotide-binding oligomerization domain containing 2 (NOD2) 3020insC (rs2066847) genes. Odds ratios were estimated for non-Hispanic whites and several ethnic subgroups using 2-sided tests. Consistent with previous findings, odds ratios were increased for "new" participant TNF -308A carriers (NHL: per-allele odds ratio (OR(allelic)) = 1.10, P(trend) = 0.001; diffuse large B-cell lymphoma (DLBCL): OR(allelic) = 1.23, P(trend) = 0.004). In the combined population, odds ratios were increased for TNF -308A carriers (NHL: OR(allelic) = 1.13, P(trend) = 0.0001; DLBCL: OR(allelic) = 1.25, P(trend) = 3.7 x 10(-6); marginal zone lymphoma: OR(allelic) = 1.35, P(trend) = 0.004) and LTA 252G carriers (DLBCL: OR(allelic) = 1.12, P(trend) = 0.006; mycosis fungoides: OR(allelic) = 1.44, P(trend) = 0.015). The LTA 252A>G/TNF -308G>A haplotype containing the LTA/TNF variant alleles was strongly associated with DLBCL (P = 2.9 x 10(-8)). Results suggested associations between IL10 -3575T>A and DLBCL (P(trend) = 0.02) and IL10 -1082A>G and mantle cell lymphoma (P(trend) = 0.04). These findings strengthen previous results for DLBCL and the LTA 252A>G/TNF -308A locus and provide robust evidence that these TNF/LTA gene variants, or others in linkage disequilibrium, are involved in NHL etiology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20047977      PMCID: PMC2842204          DOI: 10.1093/aje/kwp383

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  38 in total

1.  Sun exposure may protect against non-Hodgkin lymphoma: a case-control study.

Authors:  Ann Maree Hughes; Bruce K Armstrong; Claire M Vajdic; Jennifer Turner; Andrew E Grulich; Lin Fritschi; Sam Milliken; John Kaldor; Geza Benke; Anne Kricker
Journal:  Int J Cancer       Date:  2004-12-10       Impact factor: 7.396

2.  An investigation of polymorphism in the interleukin-10 gene promoter.

Authors:  D M Turner; D M Williams; D Sankaran; M Lazarus; P J Sinnott; I V Hutchinson
Journal:  Eur J Immunogenet       Date:  1997-02

3.  Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus.

Authors:  C O Jacob; Z Fronek; G D Lewis; M Koo; J A Hansen; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

4.  Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus-negative participants in San Francisco.

Authors:  Elizabeth A Holly; Paige M Bracci
Journal:  Am J Epidemiol       Date:  2003-08-15       Impact factor: 4.897

5.  Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers.

Authors:  Nilanjan Chatterjee; Patricia Hartge; James R Cerhan; Wendy Cozen; Scott Davis; Naoko Ishibe; Joanne Colt; Lynn Goldin; Richard K Severson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-09       Impact factor: 4.254

6.  Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-alpha promoter gene.

Authors:  Sheng-Yow Ho; Ying-Jan Wang; Hen-Li Chen; Chih-Hung Chen; Chih-Jen Chang; Po-Jen Wang; Helen H W Chen; How-Ran Guo
Journal:  Cancer Causes Control       Date:  2004-09       Impact factor: 2.506

7.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.

Authors:  A G Wilson; J A Symons; T L McDowell; H O McDevitt; G W Duff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

8.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.

Authors:  Sandeep S Dave; George Wright; Bruce Tan; Andreas Rosenwald; Randy D Gascoyne; Wing C Chan; Richard I Fisher; Rita M Braziel; Lisa M Rimsza; Thomas M Grogan; Thomas P Miller; Michael LeBlanc; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Joseph M Connors; Peter M Lansdorp; Qin Ouyang; T Andrew Lister; Andrew J Davies; Andrew J Norton; H Konrad Muller-Hermelink; German Ott; Elias Campo; Emilio Montserrat; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Liming Yang; John Powell; Hong Zhao; Neta Goldschmidt; Michael Chiorazzi; Louis M Staudt
Journal:  N Engl J Med       Date:  2004-11-18       Impact factor: 91.245

9.  Body mass index, leptin and leptin receptor polymorphisms, and non-hodgkin lymphoma.

Authors:  Christine F Skibola; Elizabeth A Holly; Matthew S Forrest; Alan Hubbard; Paige M Bracci; Danica R Skibola; Christine Hegedus; Martyn T Smith
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-05       Impact factor: 4.254

10.  Immunoregulatory role of interleukin 10 in rheumatoid arthritis.

Authors:  P D Katsikis; C Q Chu; F M Brennan; R N Maini; M Feldmann
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

View more
  72 in total

1.  Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma.

Authors:  Mark P Purdue; Qing Lan; Rachel Bagni; William G Hocking; Dalsu Baris; Douglas J Reding; Nathaniel Rothman
Journal:  Cancer Res       Date:  2011-06-01       Impact factor: 12.701

2.  DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma.

Authors:  Rita Shaknovich; Huimin Geng; Nathalie A Johnson; Lucas Tsikitas; Leandro Cerchietti; John M Greally; Randy D Gascoyne; Olivier Elemento; Ari Melnick
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

3.  Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin's lymphoma in veterans from the United States.

Authors:  Jill Koshiol; Tram Kim Lam; Gloria Gridley; David Check; Linda Morris Brown; Ola Landgren
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

Review 4.  Familial predisposition and genetic risk factors for lymphoma.

Authors:  James R Cerhan; Susan L Slager
Journal:  Blood       Date:  2015-09-24       Impact factor: 22.113

5.  Common immune-related exposures/conditions and risk of non-Hodgkin lymphoma: a case-control study of disease-discordant twin pairs.

Authors:  Jun Wang; Thomas M Mack; Ann S Hamilton; Amie E Hwang; Bharat N Nathwani; Kamil Masood; Laura H Buchanan; Leslie Bernstein; Dennis M Deapen; Otoniel Martínez-Maza; Wendy Cozen
Journal:  Am J Epidemiol       Date:  2015-08-12       Impact factor: 4.897

Review 6.  Cancer biomarkers in HIV patients.

Authors:  Richard F Ambinder; Kishor Bhatia; Otoniel Martinez-Maza; Ronald Mitsuyasu
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

7.  Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

Authors:  Hervé Ghesquières; Matthew J Maurer; Olivier Casasnovas; Stephen M Ansell; Beth R Larrabee; Eva Lech-Maranda; Anne J Novak; Anne-Laure Borrel; Susan L Slager; Pauline Brice; Cristine Allmer; Annie Brion; Steven C Ziesmer; Franck Morschhauser; Thomas M Habermann; Isabelle Gaillard; Brian K Link; Aspasia Stamatoullas; Christophe Fermé; Ahmet Dogan; William R Macon; Josée Audouin; James R Cerhan; Gilles Salles
Journal:  Cytokine       Date:  2013-09-03       Impact factor: 3.861

8.  Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma.

Authors:  James R Cerhan; Zachary S Fredericksen; Alice H Wang; Thomas M Habermann; Neil E Kay; William R Macon; Julie M Cunningham; Tait D Shanafelt; Stephen M Ansell; Timothy G Call; Thomas E Witzig; Susan L Slager; Mark Liebow
Journal:  Int J Mol Epidemiol Genet       Date:  2011-04-05

9.  Genetic variation in Th1/Th2 pathway genes and risk of non-Hodgkin lymphoma: a pooled analysis of three population-based case-control studies.

Authors:  Qing Lan; Sophia S Wang; Idan Menashe; Bruce Armstrong; Yawei Zhang; Patricia Hartge; Mark P Purdue; Theodore R Holford; Lindsay M Morton; Anne Kricker; James R Cerhan; Andrew Grulich; Wendy Cozen; Shelia H Zahm; Meredith Yeager; Claire M Vajdic; Maryjean Schenk; Brian Leaderer; Jeff Yuenger; Richard K Severson; Nilanjan Chatterjee; Stephen J Chanock; Tongzhang Zheng; Nathaniel Rothman
Journal:  Br J Haematol       Date:  2011-03-21       Impact factor: 6.998

Review 10.  Risk factors for etiology and prognosis of mantle cell lymphoma.

Authors:  Yu Wang; Shuangge Ma
Journal:  Expert Rev Hematol       Date:  2014-02-22       Impact factor: 2.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.